497P Sintilimab in Combination with Anlotinib in Advanced NSCLC Treated with First-Line PD-1 Antibodies: an Open, Single-Arm, Phase II Trial
Annals of Oncology（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined